These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 975177)

  • 1. [Clinical evaluation of pyridinolcarbamate effect on patients with obliterating atherosclerosis (author's transl)].
    Roztocil K; Oliva I; Linhart J; Prerovský I; Modr Z
    Cas Lek Cesk; 1976 Aug; 115(33-34):1051-5. PubMed ID: 975177
    [No Abstract]   [Full Text] [Related]  

  • 2. [Late results of the pyridinolcarbamate treatment of thrombotic obliterating arterial diseases of the extremities].
    Fisanovich TI; Tolstova LG
    Khirurgiia (Mosk); 1979 Sep; (9):76-80. PubMed ID: 502312
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of arteriosclerotic peripheral chronic obliterating arteriopathies (A.P.C.O.) of the lower extremities with a new pharmacologic combination].
    Bagliani A; Borri P; Parravicini R
    Minerva Cardioangiol; 1975 Nov; 23(11):701-10. PubMed ID: 1223674
    [No Abstract]   [Full Text] [Related]  

  • 4. The effect of pyridinolcarbamate after acute and chronic administration in patients with atherosclerosis obliterans.
    Roztocil K; Oliva J; Linhart J; Prerovský I; Modr Z
    Int J Clin Pharmacol Biopharm; 1977 Mar; 15(3):135-8. PubMed ID: 844932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Results obtained with prodectin in arteriosclerotic arterial obliteration of the lower extremities.
    Hunyi L
    Ther Hung; 1976; 24(2):67-71. PubMed ID: 982342
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparison of conservative (Prodectin) treatment and surgical intervention in arteriosclerotic obliterative diseases of the lower extremities.
    Hunyi L
    Ther Hung; 1978; 26(2):77-80. PubMed ID: 684660
    [No Abstract]   [Full Text] [Related]  

  • 7. [Effectiveness of pyridinolcarbamate in the overall treatment of infiltrative and cavernous-fibrous pulmonary tuberculosis].
    Makinskiĭ AI; Safarov RN; Fondaminskaia LD; Semenova AS; Fedotova NN
    Probl Tuberk; 1979 Jan; (1):26-30. PubMed ID: 368764
    [No Abstract]   [Full Text] [Related]  

  • 8. [The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis].
    Pola P
    Minerva Cardioangiol; 1975 Apr; 23(4):261-9. PubMed ID: 1095958
    [No Abstract]   [Full Text] [Related]  

  • 9. [The importance of pyridinolcarbamate and clofibrate association in the treatment of arteriosclerosis].
    Pola P
    J Pharm Sci; 1975 Jan; 64(1):261-9. PubMed ID: 1094102
    [No Abstract]   [Full Text] [Related]  

  • 10. [Influence of pyridinolcarbamate on platelet aggregation in diabetic subjects with ischemic cardiopathy].
    Citarrella P; Abbadessa V; Pecorella M; Cajozzo A
    Boll Soc Ital Cardiol; 1977; 22(7):1036-41. PubMed ID: 618239
    [No Abstract]   [Full Text] [Related]  

  • 11. [The pyridinolcarbamate-clofibrate combination in the treatment of vascular diseases in diabetics].
    Parodi FA; Caputo G
    Clin Ter; 1976 Dec; 79(6):571-81. PubMed ID: 1009761
    [No Abstract]   [Full Text] [Related]  

  • 12. [Therapeutic efficacy of pyridinolcarbamate (Anginin) in patients with combined cerebral and peripheral arteriosclerosis].
    Majkowski J; Lysakowska-Sernicka K; Gajewska A; Bilińska-Nigot B; Ostrowski K; Semenicki K
    Neurol Neurochir Pol; 1978; 12(4):387-96. PubMed ID: 714218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind crossoer clinical trial of pyridinolcarbamate in peripheral arterial disease (arteriosclerosis obliterans).
    Walton KW; Craig GM; Prior P; Waterhouse JA; Skilton J
    Br Heart J; 1973 Feb; 35(2):211-9. PubMed ID: 4570447
    [No Abstract]   [Full Text] [Related]  

  • 14. [Pyridinolcarbamate (anginin) in the treatment of diabetic angiopathies].
    Tirkina TN; Aleksandrova LM; Kliachko VR; Mazovetskiĭ AG
    Ter Arkh; 1974; 46(1):107-10. PubMed ID: 4453966
    [No Abstract]   [Full Text] [Related]  

  • 15. Pyridinolcarbamate in the long-term treatment of ischaemic heart disease.
    Gulyás A; Szám I
    Ther Hung; 1976; 24(2):63-6. PubMed ID: 982341
    [No Abstract]   [Full Text] [Related]  

  • 16. [Treatment of atherosclerosis by pyridinolcarbamate. Review of the history of the introduction of pyridinolcarbamate and its clinical results].
    Shimamoto T
    Rev Atheroscler (Paris); 1968; 10(3):67-84. PubMed ID: 5746502
    [No Abstract]   [Full Text] [Related]  

  • 17. [Therapeutic results with combination of pyridinolcarbamate and clofibrate in atherosclerotic patients].
    Valiensi M; Riboli E; Lombardi M
    Minerva Cardioangiol; 1976 Feb; 24(2):148-54. PubMed ID: 1256654
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical and plethysmographic evaluation in patients with peripheral arteriopathies treated with pyridinolcarbamate].
    Lucero Eseverri JA; Fajardo JD; Velles Aguirre L; Quijano E; Ciliberti E; Lucarelli R
    Prensa Med Argent; 1970 Apr; 57(8):394-8. PubMed ID: 5517707
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pyridinolcarbamate treatment of atherosclerosis obliterans analysed by toe plethysmography].
    Motomiya T
    Nihon Naika Gakkai Zasshi; 1970 Feb; 59(2):117-25. PubMed ID: 4910199
    [No Abstract]   [Full Text] [Related]  

  • 20. Pyridinolcarbamate treatment of atherosclerosis obliterans analysed by toe plethysmography.
    Motomiya T; Atsumi T; Isokane N; Yamashita S; Sano T
    Jpn Heart J; 1970 Sep; 11(5):433-49. PubMed ID: 4921577
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.